[1] Charif Chefchaouni M, Belmekki M, Hajji Z, et al. Ophthalmic manifestations of acute leukemia]
[J]. J Fr Ophtalmol, 2002, 25(1): 62-6.

[2] Alrobaian M A, Henderson A D. Neuro-Ophthalmic Manifestations of Acute Leukemia
[J]. J Neuroophthalmol, 2021, 41(4): e584-e590.

[3] Rosenthal A R. Ocular manifestations of leukemia. A review
[J]. Ophthalmology, 1983, 90(8): 899-905.

[4] Sharma T, Grewal J, Gupta S, et al. Ophthalmic manifestations of acute leukaemias: the ophthalmologist's role
[J]. Eye (Lond), 2004, 18(7): 663-72.

[5] Duane T D, Osher R H, Green W R. White centered hemorrhages: their significance
[J]. Ophthalmology, 1980, 87(1): 66-9.

[6] Tseng M Y, Chen Y C, Lin Y Y, et al. Simultaneous bilateral central retinal vein occlusion as the initial presentation of acute myeloid leukemia
[J]. Am J Med Sci, 2010, 339(4): 387-9.

[7] Talcott K E, Garg R J, Garg S J. Ophthalmic manifestations of leukemia
[J]. Curr Opin Ophthalmol, 2016, 27(6): 545-551.

[8] Reddy S C, Menon B S. A prospective study of ocular manifestations in childhood acute leukaemia
[J]. Acta Ophthalmol Scand, 1998, 76(6): 700-3.

[9] Swartz M, Jampol L M. Comma-shaped venular segments of conjunctiva in chronic granulocytic leukemia
[J]. Can J Ophthalmol, 1975, 10(4): 458-61.

[10] Malard F, Mohty M. Acute lymphoblastic leukaemia
[J]. Lancet, 2020, 395(10230): 1146-1162.

[11] Estey E, Döhner H. Acute myeloid leukaemia
[J]. Lancet, 2006, 368(9550): 1894-907.

[12] Hallek M, Shanafelt T D, Eichhorst B. Chronic lymphocytic leukaemia
[J]. Lancet, 2018, 391(10129): 1524-1537.

[13] Bay A, Yilmaz C, Yilmaz N, et al. Vincristine induced cranial polyneuropathy
[J]. Indian J Pediatr, 2006, 73(6): 531-3.

[14] Hollander D A, Aldave A J. Drug-induced corneal complications
[J]. Curr Opin Ophthalmol, 2004, 15(6): 541-8.

[15] Pavlu J, Czepulkowski B, Kaczmarski R, et al. Early blastic transformation with CNS infiltration in a patient with chronic myeloid leukaemia treated with imatinib
[J]. Lancet Oncol, 2005, 6(2): 128.

[16] Saglio G, Kim D W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
[J]. N Engl J Med, 2010, 362(24): 2251-9.

[17] Breccia M, Gentilini F, Cannella L, et al. Ocular side effects in chronic myeloid leukemia patients treated with imatinib
[J]. Leuk Res, 2008, 32(7): 1022-5.

[18] Basu S, Das T, Biswas G. Bilateral toxoplasma retinochoroiditis in a patient with chronic myeloid leukemia treated with imatinib mesylate
[J]. Ocul Immunol Inflamm, 2010, 18(1): 64-5.

[19] Radaelli F, Vener C, Ripamonti F, et al. Conjunctival hemorrhagic events associated with imatinib mesylate
[J]. Int J Hematol, 2007, 86(5): 390-3.

[20] Moore D C, Muslimani A, Sinclair P. Nilotinib-Induced Ocular Toxicity: A Case Report
[J]. Am J Ther, 2018, 25(5): e570-e571.

[21] Filipovich A H, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report
[J]. Biol Blood Marrow Transplant, 2005, 11(12): 945-56.

[22] Jagasia M H, Greinix H T, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report
[J]. Biol Blood Marrow Transplant, 2015, 21(3): 389-401 e1.

[23] Ogawa Y, Kim S K, Dana R, et al. International Chronic Ocular Graft-vs-Host-Disease (GVHD) Consensus Group: proposed diagnostic criteria for chronic GVHD (Part I)
[J]. Sci Rep, 2013, 3: 3419.

[24] Shikari H, Antin J H, Dana R. Ocular graft-versus-host disease: a review
[J]. Surv Ophthalmol, 2013, 58(3): 233-51.

[25] Braun R, Holler E. Acute Ocular Graft-versus-Host Disease
[J]. N Engl J Med, 2017, 377(7): 676.